ALTG December 2018 News letter
2018 has been another outstanding year for the Australasian Lung Cancer Trials Group (ALTG). One of the significant highlights for 2018 has been the renewed funding arrangement from Cancer Australia for the next three years. Not only does this provide financial sustainability for the program over this time, it also recognises the enormous contribution the ALTG program offers lung cancer patients Australia wide
The year began with recruiting participants across a diverse portfolio of clinical trials, with recruitment numbers tracking on or above schedule. We are working hard to offer new treatments to as many eligible lung cancer patients as possible. So far this year, the ALTG collaborative group recruited over 170 patients to our clinical trial portfolio and added at least one new trial to our extensive portfolio.
Education and events
One of the most important aspects of ALTG is connecting research outcomes, information and evidence to the scientific, healthcare professional and patient communities.
Developing our next generation of researchers saw ALTG host our fourth annual preceptorship workshop. This event has become a must do for any new or emerging lung cancer consultant or researcher and in 2019, the preceptorship workshop will be held in October. For further details, visit our website here.
Our 3rd annual symposium was another fantastic and successful event with exceptional international and national speakers showcasing their knowledge and expertise to an eager audience. An inspirational tone for the event was set by Mr Chris Draft – Founder, President and CEO of the Chris Draft Family Foundation – who share his moving story about his wife, who sadly lost her battle to lung cancer in 2011.
New for 2018 was the addition of our speaking tours with the aim to increase ALTG presence in the local health care and patient communities. Positioned nicely after the World Lung Cancer Conference, the speaking tours were also an informal approach to shining a light on the progress to-date of research and the impact clinical trial outcomes have on the lung cancer space globally.
The ALTG membership continues to grow with over 740 members across Australia and New Zealand. We look forward to 2019 and building on the successes of this year to take ALTG’s scientific and educational endeavours to new heights and prominence on a global stage.
Thank you for all your support throughout the year and we wish you and your family a happy holiday.